OBJECTIVES:Evaluate toxicity of two treatment arms, A (cetuximab) and B (bevacizumab), when combined with gemcitabine, and chemoradiation in patients with completely resected pancreatic carcinoma. Secondary objectives included overall survival (OS) and disease-free survival (DFS). METHODS:Patients with R0/R1 resection were randomized 1:1 to cetuximab or bevacizumab administered in combination with gemcitabine for two treatment cycles. Next three cycles included concurrent cetuximab/bevacizumab plus chemoradiation, followed by one cycle of cetuximab/bevacizumab. Cycles 7-12 included cetuximab/bevacizumab with gemcitabine. Cycles were 2 weeks. Frequency of specific toxicities was summarized for each treatment arm at two times during the study, after chemotherapy but prior to chemoradiation and after all therapy. RESULTS: A total of 127 patients were randomized (A, n = 65; B, n = 62). Prior to chemoradiation, the overall rate for toxicities of interest was 10% for arm A and 2% for arm B. After all therapy, the overall rates for toxicities of interest were 30 and 25% for arms A and B, respectively. Overall median OS and DFS were 17 and 11 months, respectively, which is not a significant improvement over expected survival rates for historical controls. CONCLUSIONS: Both treatments were tolerable with manageable toxicities, and were safe enough for a phase III trial had this been indicated.
RCT Entities:
OBJECTIVES: Evaluate toxicity of two treatment arms, A (cetuximab) and B (bevacizumab), when combined with gemcitabine, and chemoradiation in patients with completely resected pancreatic carcinoma. Secondary objectives included overall survival (OS) and disease-free survival (DFS). METHODS:Patients with R0/R1 resection were randomized 1:1 to cetuximab or bevacizumab administered in combination with gemcitabine for two treatment cycles. Next three cycles included concurrent cetuximab/bevacizumab plus chemoradiation, followed by one cycle of cetuximab/bevacizumab. Cycles 7-12 included cetuximab/bevacizumab with gemcitabine. Cycles were 2 weeks. Frequency of specific toxicities was summarized for each treatment arm at two times during the study, after chemotherapy but prior to chemoradiation and after all therapy. RESULTS: A total of 127 patients were randomized (A, n = 65; B, n = 62). Prior to chemoradiation, the overall rate for toxicities of interest was 10% for arm A and 2% for arm B. After all therapy, the overall rates for toxicities of interest were 30 and 25% for arms A and B, respectively. Overall median OS and DFS were 17 and 11 months, respectively, which is not a significant improvement over expected survival rates for historical controls. CONCLUSIONS: Both treatments were tolerable with manageable toxicities, and were safe enough for a phase III trial had this been indicated.
Authors: William F Regine; Kathryn A Winter; Ross Abrams; Howard Safran; John P Hoffman; Andre Konski; Al B Benson; John S Macdonald; Tyvin A Rich; Christopher G Willett Journal: Ann Surg Oncol Date: 2011-03-10 Impact factor: 5.344
Authors: Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian Journal: Cancer Res Date: 2014-06-01 Impact factor: 12.701
Authors: Hedy L Kindler; Gregory Friberg; Deepti A Singh; Gershon Locker; Sreenivasa Nattam; Mark Kozloff; David A Taber; Theodore Karrison; Abraham Dachman; Walter M Stadler; Everett E Vokes Journal: J Clin Oncol Date: 2005-11-01 Impact factor: 44.544
Authors: Aimery de Gramont; Eric Van Cutsem; Hans-Joachim Schmoll; Josep Tabernero; Stephen Clarke; Malcolm J Moore; David Cunningham; Thomas H Cartwright; J Randolph Hecht; Fernando Rivera; Seock-Ah Im; György Bodoky; Ramon Salazar; Frédérique Maindrault-Goebel; Einat Shacham-Shmueli; Emilio Bajetta; Martina Makrutzki; Aijing Shang; Thierry André; Paulo M Hoff Journal: Lancet Oncol Date: 2012-11-16 Impact factor: 41.316
Authors: John P Neoptolemos; Daniel H Palmer; Paula Ghaneh; Eftychia E Psarelli; Juan W Valle; Christopher M Halloran; Olusola Faluyi; Derek A O'Reilly; David Cunningham; Jonathan Wadsley; Suzanne Darby; Tim Meyer; Roopinder Gillmore; Alan Anthoney; Pehr Lind; Bengt Glimelius; Stephen Falk; Jakob R Izbicki; Gary William Middleton; Sebastian Cummins; Paul J Ross; Harpreet Wasan; Alec McDonald; Tom Crosby; Yuk Ting Ma; Kinnari Patel; David Sherriff; Rubin Soomal; David Borg; Sharmila Sothi; Pascal Hammel; Thilo Hackert; Richard Jackson; Markus W Büchler Journal: Lancet Date: 2017-01-25 Impact factor: 79.321
Authors: Philip A Philip; Jacqueline Benedetti; Christopher L Corless; Ralph Wong; Eileen M O'Reilly; Patrick J Flynn; Kendrith M Rowland; James N Atkins; Barry C Mirtsching; Saul E Rivkin; Alok A Khorana; Bryan Goldman; Cecilia M Fenoglio-Preiser; James L Abbruzzese; Charles D Blanke Journal: J Clin Oncol Date: 2010-07-06 Impact factor: 44.544
Authors: Henry Q Xiong; Arthur Rosenberg; Albert LoBuglio; William Schmidt; Robert A Wolff; John Deutsch; Michael Needle; James L Abbruzzese Journal: J Clin Oncol Date: 2004-07-01 Impact factor: 44.544
Authors: Helmut Oettle; Peter Neuhaus; Andreas Hochhaus; Jörg Thomas Hartmann; Klaus Gellert; Karsten Ridwelski; Marco Niedergethmann; Carl Zülke; Jörg Fahlke; Michael B Arning; Marianne Sinn; Axel Hinke; Hanno Riess Journal: JAMA Date: 2013-10-09 Impact factor: 56.272
Authors: Juan W Valle; Daniel Palmer; Richard Jackson; Trevor Cox; John P Neoptolemos; Paula Ghaneh; Charlotte L Rawcliffe; Claudio Bassi; Deborah D Stocken; David Cunningham; Derek O'Reilly; David Goldstein; Bridget A Robinson; Christos Karapetis; Andrew Scarfe; Francois Lacaine; Juhani Sand; Jakob R Izbicki; Julia Mayerle; Christos Dervenis; Attila Oláh; Giovanni Butturini; Pehr A Lind; Mark R Middleton; Alan Anthoney; Kate Sumpter; Ross Carter; Markus W Büchler Journal: J Clin Oncol Date: 2014-01-13 Impact factor: 44.544
Authors: Prajnan Das; Robert A Wolff; James L Abbruzzese; Gauri R Varadhachary; Douglas B Evans; Jean Nicolas Vauthey; Andrew Baschnagel; Marc E Delclos; Sunil Krishnan; Nora A Janjan; Christopher H Crane Journal: Radiat Oncol Date: 2006-10-24 Impact factor: 3.481
Authors: Leonel Pekarek; Oscar Fraile-Martinez; Cielo Garcia-Montero; Miguel A Saez; Ines Barquero-Pozanco; Laura Del Hierro-Marlasca; Patricia de Castro Martinez; Adoración Romero-Bazán; Miguel A Alvarez-Mon; Jorge Monserrat; Natalio García-Honduvilla; Julia Buján; Melchor Alvarez-Mon; Luis G Guijarro; Miguel A Ortega Journal: Cancers (Basel) Date: 2022-04-07 Impact factor: 6.575